Lexeo Therapeutics (NASDAQ:LXEO) Price Target Lowered to $13.00 at HC Wainwright

Lexeo Therapeutics (NASDAQ:LXEO) had its price objective reduced by HC Wainwright from $15.00 to $13.00 in a report released on Tuesday morning, MarketBeat.com reports. They currently have a buy rating on the stock.

Other equities analysts have also recently issued reports about the stock. Guggenheim began coverage on shares of Lexeo Therapeutics in a research note on Wednesday, October 15th. They issued a “buy” rating and a $30.00 target price for the company. Chardan Capital boosted their target price on shares of Lexeo Therapeutics from $15.00 to $17.00 and gave the company a “buy” rating in a research note on Tuesday, October 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lexeo Therapeutics in a research note on Wednesday, October 8th. Oppenheimer assumed coverage on shares of Lexeo Therapeutics in a report on Thursday, July 31st. They issued an “outperform” rating and a $20.00 price target for the company. Finally, Leerink Partners boosted their price target on shares of Lexeo Therapeutics from $9.00 to $20.00 and gave the stock an “outperform” rating in a report on Tuesday, October 7th. Seven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $18.57.

Lexeo Therapeutics Trading Up 4.1%

Shares of NASDAQ LXEO opened at $9.60 on Tuesday. Lexeo Therapeutics has a 12 month low of $1.45 and a 12 month high of $11.72. The company has a 50 day simple moving average of $6.10 and a two-hundred day simple moving average of $4.50. The stock has a market cap of $518.40 million, a price-to-earnings ratio of -2.94 and a beta of 1.66.

Lexeo Therapeutics (NASDAQ:LXEO) last posted its earnings results on Thursday, August 14th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.64) by $0.04. Analysts forecast that Lexeo Therapeutics will post -3.14 EPS for the current year.

Insider Transactions at Lexeo Therapeutics

In other news, insider Eric Adler sold 3,382 shares of the company’s stock in a transaction on Friday, October 17th. The shares were sold at an average price of $8.94, for a total transaction of $30,235.08. Following the completion of the sale, the insider owned 73,261 shares of the company’s stock, valued at $654,953.34. This represents a 4.41% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Tai Sandi See sold 3,888 shares of the company’s stock in a transaction on Friday, October 17th. The stock was sold at an average price of $8.94, for a total transaction of $34,758.72. Following the sale, the insider directly owned 65,862 shares of the company’s stock, valued at $588,806.28. The trade was a 5.57% decrease in their position. The disclosure for this sale can be found here. Insiders sold 29,091 shares of company stock valued at $232,007 over the last 90 days. 5.30% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Lexeo Therapeutics

A number of large investors have recently modified their holdings of the business. CWM LLC grew its holdings in shares of Lexeo Therapeutics by 82.2% during the third quarter. CWM LLC now owns 18,864 shares of the company’s stock worth $125,000 after buying an additional 8,513 shares in the last quarter. Vestal Point Capital LP grew its holdings in shares of Lexeo Therapeutics by 184.1% during the second quarter. Vestal Point Capital LP now owns 3,228,161 shares of the company’s stock worth $12,977,000 after buying an additional 2,091,912 shares in the last quarter. Frazier Life Sciences Management L.P. grew its holdings in shares of Lexeo Therapeutics by 363.1% during the second quarter. Frazier Life Sciences Management L.P. now owns 4,424,725 shares of the company’s stock worth $17,787,000 after buying an additional 3,469,210 shares in the last quarter. BNP Paribas Financial Markets grew its holdings in shares of Lexeo Therapeutics by 20.4% during the second quarter. BNP Paribas Financial Markets now owns 48,434 shares of the company’s stock worth $195,000 after buying an additional 8,223 shares in the last quarter. Finally, Bridgeway Capital Management LLC grew its holdings in shares of Lexeo Therapeutics by 39.1% in the second quarter. Bridgeway Capital Management LLC now owns 53,400 shares of the company’s stock valued at $215,000 after purchasing an additional 15,000 shares during the period. Hedge funds and other institutional investors own 60.67% of the company’s stock.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.